stockportfolio.pro
Arcutis Biotherapeutics, Inc. (ARQT)
Healthcare · Biotechnology · NasdaqGS
Arcutis Biotherapeutics, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $3.69M | $59.61M | $196.54M | $376.07M |
| Gross profit | — | — | — | — | $2.93M | $54.62M | $177.41M | $339.38M |
| Net income | $-19.25M | $-42.00M | $-135.68M | $-206.36M | $-311.46M | $-262.14M | $-140.04M | $-16.14M |
| Net margin | — | — | — | — | -8449.8% | -439.8% | -71.3% | -4.3% |
Source: Arcutis Biotherapeutics, Inc. SEC filings (10-K).
Explore 8 years of Arcutis Biotherapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ARQT in your portfolio →
Arcutis Biotherapeutics, Inc. financial history by metric
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Arcutis Biotherapeutics, Inc. — frequently asked questions
What is Arcutis Biotherapeutics, Inc.'s revenue?
Arcutis Biotherapeutics, Inc. (ARQT) reported revenue of $376.07M for fiscal year 2025, up 91.3% from the prior year, according to its SEC filings.
Is Arcutis Biotherapeutics, Inc. profitable?
No — ARQT reported a net loss of $-16.14M in fiscal 2025.
What is ARQT's P/E ratio?
Arcutis Biotherapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Arcutis Biotherapeutics, Inc. have?
As of fiscal year 2025, ARQT carried roughly $108.96M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Arcutis Biotherapeutics, Inc.'s gross margin?
ARQT's gross margin was 90.2% in fiscal 2025 — gross profit of $339.38M on revenue of $376.07M.
What is Arcutis Biotherapeutics, Inc.'s market cap?
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalization of about $3.05B, based on the latest data in our nightly-refreshed cache.
When does Arcutis Biotherapeutics, Inc.'s fiscal year end?
ARQT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Arcutis Biotherapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.